A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

This study is testing a combination of two targeted drugs — VS-6766 (a RAF/MEK inhibitor) and cetuximab (a drug that targets a protein called EGFR) — in patients with metastatic colorectal cancer that has a KRAS gene mutation. KRAS mutations typically make colorectal cancer resistant to many treatments. **You may be eligible if...** - You have metastatic colorectal cancer with a confirmed KRAS mutation - You have already tried standard chemotherapy drugs (5-FU/capecitabine, oxaliplatin, irinotecan, and bevacizumab) - Your cancer is measurable on scans - You are in good enough physical health **You may NOT be eligible if...** - Your cancer does not have a KRAS mutation - You have not yet tried standard chemotherapy options - You have severe heart, kidney, or liver problems Talk to your doctor to see if this trial is right for you.